ADAR1 Capital Management
VC Fund
ADAR1 Capital Management is an investment firm.
- Total investments:
- 37
- Last investment:
- Lead investor:
- 8%
Last updated:
For AI agents: llms.txt
Industries ADAR1 Capital Management invests in
Stages ADAR1 Capital Management invests in
Countries ADAR1 Capital Management invests in
Investment Focus
Industry
- Biotechnology 5 (14%)
- Health Care 3 (8%)
- Therapeutics 3 (8%)
- Pharmaceutical 3 (8%)
- Medical 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Tarsus Pharmaceuticals
|
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases acrosstherapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis. | $125M / Post-IPO Equity / Aug 06, 2026 | |
Processa Pharmaceuticals
|
Processa Pharmaceuticals operates as a pharmaceutical company. The company focuses on development of drug products that are intended to improve the survival and quality of life for patients who have unmet medical need. | $200M / Post-IPO Equity / Jul 29, 2026 | |
Claris Biotherapeutics
|
Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment. | $118M / Series B / Jul 28, 2026 | |
Mentari Therapeutics
|
Mentari Therapeutics is a biotechnology company developing therapies for the prevention of migraine. | $200M / Private Equity / Jul 22, 2026 | |
Freenome
|
Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $240M / Post-IPO Equity / Jul 20, 2026 | |
Whitehawk Therapeutics
|
Aadi Bioscience was founded by Dr. Neil Desai, is a clinical-stage biopharmaceutical company developing the potentially best-in-class mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases. | $87.5M / Post-IPO Equity / May 13, 2026 | |
InflaRx
|
InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application.In April 2018, InflaRx conducted a USD 117 million totalgross proceeds follow-on transaction on the US Nasdaq global select market comprised of a primary component of USD 63 million investment into InflaRx as well as a secondary component of USD 54 million to existing first-day shareholders of InflaRx. InflaRx was founded in December 2017 and is headquartered in Jena, Germany. | $150M / Post-IPO Equity / May 06, 2026 | |
CNS Pharmaceutical
|
CNS Pharmaceuticals is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. CNS may also pursue the development of Berubicin to treat additional diseases, including pancreatic and ovarian cancers and lymphoma. CNS may also develop combination therapies that include Berubicin. | $22.5M / Post-IPO Equity / May 04, 2026 | |
Climb Bio
|
Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders. The company leverages its expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline.Eliem Therapeutics develops and commercializes potentially“best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. | $110M / Post-IPO Equity / Apr 28, 2026 | |
Kiora Pharmaceuticals
|
EyeGate Pharmaceuticals is a clinical-stage specialty pharmaceutical company that develops medicines to treat eye diseases using its non-invasive, iontophoretic drug-delivery system. It is developing a proprietary platform of medicines to treat diseases of the eye using its unique, non-invasive, iontophoretic drug-delivery system called EyeGateÂII. This proprietary technology platform is based on over 10-years of development at the Bascom Palmer Eye Institute at the University of Miami and has been tested extensively in both pre-clinical and human studies in Europe. Because of the human eye's special anatomy, effective delivery of medicines to treat chronic diseases in the mid and posterior segments of the eye is less than adequate. They believe the EyeGate II Delivery System will offer both physicians and patients an important new alternative in advancing the treatment of eye disease. | $5M / Post-IPO Equity / Apr 07, 2026 | |
| See all 37 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does ADAR1 Capital Management invest in?
ADAR1 Capital Management invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity stage. Most of the 37 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did ADAR1 Capital Management last invest?
The most recent investment recorded for ADAR1 Capital Management closed in Aug 2026. Shizune tracks 37 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
